888
Participants
Start Date
December 27, 2018
Primary Completion Date
October 30, 2021
Study Completion Date
July 31, 2022
GnRH-ant protocol
Recombinant FSH (Gonal-f®) will be administrated as routinely practiced by investigators. FSH doses will be adjusted according to the clinical experiences of investigators.The GnRH-ant (Cetrotide®) will be initiated in a fixed protocol on stimulation days 5 or 6 per the investigator's ART protocol.
GnRH-a long protocol
The GnRH-a (Diphereline® or Decapetyl®) 0.1mg will be administered for about14 to 20 days for down-regulation. Gonal-f® will be administrated as routinely practiced by investigators. GnRH-a types, GnRH-a and FSH doses will be adjusted according to the clinical experiences of investigators in each site.
RECRUITING
Peking University Third Hospital, Beijing
RECRUITING
Jiangsu Provincial Hospital, Nanjing
RECRUITING
The second hospital of Hebei Medical University, Baoding
RECRUITING
The third hospital of Zhengzhoui Medical University, Zhengzhou
Collaborators (1)
Merck Serono GmbH, Germany
INDUSTRY
Fountain Medical Development Co., Ltd.
INDUSTRY
Guangzhou KingMed Center for Clinical Lab.Co., Ltd
UNKNOWN
Peking University Third Hospital
OTHER